Schedule One - BiVictriX Therapeutics plc | RNS | Ticker

Schedule One - BiVictriX Therapeutics plc

RNS Announcement

RNS Number : 4536F

AIM

16 July 2021

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

BiVictriX plc, to become BiVictriX Therapeutics plc ("BVX" or the "Company") shortly prior to Admission

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES):

Current:

Slater Heelis Limited

86 Deansgate

Manchester

United Kingdom

M3 2ER

Trading address and registered office post- Admission:

Alderley Park

Congleton Road

Nether Alderley

Macclesfield

SK10 4TG

COUNTRY OF INCORPORATION:

England and Wales

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

www.bivictrix.com

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

BVX is a UK based drug development company which was incorporated in February 2016 and has developed its proprietary Bi-Cygni^® technology. This technology utilises Antibody Drug Conjugates ("ADC"s), an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia, the first condition which BVX intends to treat.

BVX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce cancer selective therapeutics. The Bi-Cygni^® technology has been developed to exploit this concept and expedite the development of bispecific therapeutics with an improved therapeutic index. Based on BVX's work to date, these ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs. The main country of operation is in the UK.

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

TBC ordinary shares of £0.01 par value each in the capital of the Company ("Ordinary Shares").

Issue price: TBC

No restrictions on transferability.

CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Capital to be raised on Admission: TBC

Anticipated market capitalisation on Admission: TBC

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

TBC

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

N/A

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Existing Directors:

Tiffany Jane Thorn (Chief Executive Officer)

Proposed Directors:

Iain Gladstone Ross (Non-Executive Chairman)

Professor Robert Edward Hawkins (Non-Executive Director)

Susan Day Lowther (Non-Executive Director)

William Drummond Paris (Senior Non-Executive Director)

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Name	Number of Ordinary Shares*	Percentage of Existing Ordinary Shares	Number of Ordinary Shares immediately following Admission	Percentage of Enlarged Issued Share Capital
Development Bank of Wales	31,178	31.2%	TBC	TBC
Alderley Park Ventures	21,257	21.2%	TBC	TBC
Tiffany Thorn	7,500	7.5%	TBC	TBC
Peter Jackson	4,500	4.5%	TBC	TBC
Charles Johnson	4,000	4.0%	TBC	TBC
David Evans	3,750	3.8%	TBC	TBC
Christopher Oglesby	3,515	3.5%	TBC	TBC

* Based on current BVX holding

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

N/A

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

(i) 31 December

(ii) Audited results to 31 December 2020

(iii) Accounts for 6 month period ended 30 June 2021 (to be notified by 30 September 2021); Accounts for 12 month period ended 31 December 2021 (by 30 June 2022); Accounts for 6 months ended 30 June 2022 (by 30 September 2022).

EXPECTED ADMISSION DATE:

Late July 2021

NAME AND ADDRESS OF NOMINATED ADVISER:

S.P. Angel Corporate Finance LLP, Prince Frederick House, 35-39 Maddox Street, Mayfair, London, W1S 2PP

NAME AND ADDRESS OF BROKER:

S.P. Angel Corporate Finance LLP, Prince Frederick House, 35-39 Maddox Street, Mayfair, London, W1S 2PP

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

Copies of this document will be available free of charge to the public during normal business hours on any day (Saturdays, Sundays and public holidays excepted) at the offices of S.P. Angel Corporate Finance LLP, Prince Frederick House, 35-39 Maddox Street, Mayfair, London, W1S 2PP in accordance with the AIM Rules. This document will also be available for download from the Company's website at www.bivictrix.com

THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY

BVX will adopt the QCA Corporate Governance Code, as published by the Quoted Companies Alliance.

DATE OF NOTIFICATION:

16 July 2021

NEW/ UPDATE:

New

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PAAFIFLRDRIRLIL

RNS metadata

Title: Schedule One - BiVictriX Therapeutics plc
Time: 08:00:01
Date: 16 Jul 2021
Category: Capital structure
ID: 4536F